Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$724.51M$724.51M+3.2% vs Q2 2024 Net Income$22.42M$22.42M+274.0% vs Q2 2024 EPS Diluted$0.07$0.07+250.0% vs Q2 2024 Gross Profit$286,253,000+14.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$83,819,000+111.4% Free Cash Flowderived$60,989,000+110.1% Margins · derivedGross margin39.5%+3.9 pt vs Q2 2024
Operating margin15.4%+1.8 pt vs Q2 2024
Net margin3.1%+2.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end